QRISK3 (UK)

The QRISK3-2017 algorithm recommended by NICE, including ethnicity, deprivation, smoking amount, type 1 and type 2 diabetes, BMI, SBP variability, AF, CKD, migraine, rheumatoid arthritis, SLE, severe mental illness, atypical antipsychotics, steroids and erectile dysfunction. At 10% or more NICE offers atorvastatin 20 mg; from age 85, where QRISK3 does not apply, NICE advises considering atorvastatin 20 mg.

Upload a report, lab sheet or echo picture to fill this calculator automatically.

Demographics

Age

years

25–84 years

Lipids & blood pressure

Total cholesterol

mmol/L

HDL cholesterol

mmol/L

Systolic BP

mmHg

Ethnicity

Smoking & diabetes

Measurements

BMI

kg/m²

SD of systolic BP

mmHg

Of ≥ 2 recent readings; blank uses the cohort meanTownsend score

Deprivation (UK postcode); blank = 0

Medical history & treatment

Tap all that apply

QRISK3 · 10-year CHD, stroke or TIA

Enter age, cholesterol, systolic BP and BMI.

References

Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099.
National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline NG238, 2023 (people aged 85 and over: consider atorvastatin 20 mg).
National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline NG136, 2019 (updated 2023).